KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin (2016 - 2025)

Historic EBT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 30.17%.

  • Supernus Pharmaceuticals' EBT Margin fell 557500.0% to 30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year decrease of 141600.0%. This contributed to the annual value of 14.79% for FY2024, which is 143300.0% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' EBT Margin stood at 30.17%, which was down 557500.0% from 10.07% recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBT Margin peaked at 25.58% during Q3 2024, and registered a low of 30.17% during Q3 2025.
  • Its 5-year average for EBT Margin is 6.37%, with a median of 6.66% in 2022.
  • Per our database at Business Quant, Supernus Pharmaceuticals' EBT Margin surged by 282600bps in 2024 and then crashed by -557500bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBT Margin (Quarter) stood at 1.29% in 2021, then surged by 1529bps to 21.0% in 2022, then plummeted by -97bps to 0.6% in 2023, then skyrocketed by 2414bps to 15.15% in 2024, then plummeted by -299bps to 30.17% in 2025.
  • Its last three reported values are 30.17% in Q3 2025, 10.07% for Q2 2025, and 3.89% during Q1 2025.